BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37793876)

  • 1. [Pathogenic role of insufficiency of polycomb repressive complex in primary myelofibrosis].
    Shinoda D
    Rinsho Ketsueki; 2023; 64(9):998-1006. PubMed ID: 37793876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition.
    Sashida G; Wang C; Tomioka T; Oshima M; Aoyama K; Kanai A; Mochizuki-Kashio M; Harada H; Shimoda K; Iwama A
    J Exp Med; 2016 Jul; 213(8):1459-77. PubMed ID: 27401345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of driver and subclonal mutations in pathogenesis of primary myelofibrosis].
    Mózes R; Gángó A; Boha Z; Csomor J; Bödör C
    Magy Onkol; 2017 Mar; 61(1):36-45. PubMed ID: 28273187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis.
    Norfo R; Zini R; Pennucci V; Bianchi E; Salati S; Guglielmelli P; Bogani C; Fanelli T; Mannarelli C; Rosti V; Pietra D; Salmoiraghi S; Bisognin A; Ruberti S; Rontauroli S; Sacchi G; Prudente Z; Barosi G; Cazzola M; Rambaldi A; Bortoluzzi S; Ferrari S; Tagliafico E; Vannucchi AM; Manfredini R;
    Blood; 2014 Sep; 124(13):e21-32. PubMed ID: 25097177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoproteasome Genes Are Modulated in CD34
    Di Rosa M; Giallongo C; Romano A; Tibullo D; Li Volti G; Musumeci G; Barbagallo I; Imbesi R; Castrogiovanni P; Palumbo GA
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insufficiency of non-canonical PRC1 synergizes with JAK2V617F in the development of myelofibrosis.
    Shinoda D; Nakajima-Takagi Y; Oshima M; Koide S; Aoyama K; Saraya A; Harada H; Rahmutulla B; Kaneda A; Yamaguchi K; Furukawa Y; Koseki H; Shimoda K; Tanaka T; Sashida G; Iwama A
    Leukemia; 2022 Feb; 36(2):452-463. PubMed ID: 34497325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis.
    Fan N; Tang Y; Wu Z; Guan M; Chen B; Xu X; Ma W; Xu X; Zhang X
    Ann Hematol; 2018 Jul; 97(7):1193-1208. PubMed ID: 29560522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.
    Triviai I; Zeschke S; Rentel J; Spanakis M; Scherer T; Gabdoulline R; Panagiota V; Thol F; Heuser M; Stocking C; Kröger N
    Leukemia; 2019 Jan; 33(1):99-109. PubMed ID: 29907810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
    Hu Z; Ramos CEB; Medeiros LJ; Zhao C; Yin CC; Li S; Hu S; Wang W; Thakral B; Xu J; Verstovsek S; Lin P
    Hum Pathol; 2019 Mar; 85():290-298. PubMed ID: 30447300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.
    Al-Ghamdi YA; Lake J; Bagg A; Thakral B; Wang SA; Bueso-Ramos C; Masarova L; Verstovsek S; Rogers HJ; Hsi ED; Gralewski JH; Chabot-Richards D; George TI; Rets A; Hasserjian RP; Weinberg OK; Parilla M; Arber DA; Padilla O; Orazi A; Tam W
    Mod Pathol; 2023 Mar; 36(3):100016. PubMed ID: 36788093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes.
    Oguro H; Yuan J; Tanaka S; Miyagi S; Mochizuki-Kashio M; Ichikawa H; Yamazaki S; Koseki H; Nakauchi H; Iwama A
    J Exp Med; 2012 Mar; 209(3):445-54. PubMed ID: 22351929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 mutational status predicts poor survival in myelofibrosis.
    Guglielmelli P; Biamonte F; Score J; Hidalgo-Curtis C; Cervantes F; Maffioli M; Fanelli T; Ernst T; Winkelman N; Jones AV; Zoi K; Reiter A; Duncombe A; Villani L; Bosi A; Barosi G; Cross NC; Vannucchi AM
    Blood; 2011 Nov; 118(19):5227-34. PubMed ID: 21921040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I Diagnose Primary Myelofibrosis.
    Prakash S; Orazi A
    Am J Clin Pathol; 2022 Apr; 157(4):518-530. PubMed ID: 35238345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
    Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis.
    Morishita S; Ochiai T; Misawa K; Osaga S; Inano T; Fukuda Y; Edahiro Y; Ohsaka A; Araki M; Komatsu N
    Int J Hematol; 2021 Apr; 113(4):500-507. PubMed ID: 33389584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.
    Kuo MC; Lin TH; Sun CF; Lin TL; Wu JH; Wang PN; Huang YJ; Chang H; Huang TY; Shih LY
    J Clin Pathol; 2018 Jun; 71(6):514-521. PubMed ID: 29203554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
    Manshouri T; Verstovsek S; Harris DM; Veletic I; Zhang X; Post SM; Bueso-Ramos CE; Estrov Z
    PLoS One; 2019; 14(9):e0222912. PubMed ID: 31569199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.
    Svrlanska A; Reichel A; Schilling EM; Scherer M; Stamminger T; Reuter N
    J Virol; 2019 May; 93(9):. PubMed ID: 30814291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel targets to cure primary myelofibrosis from studies on Gata1
    Zingariello M; Martelli F; Verachi P; Bardelli C; Gobbo F; Mazzarini M; Migliaccio AR
    IUBMB Life; 2020 Jan; 72(1):131-141. PubMed ID: 31749302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.